Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: A single institution phase II study

Keyphrases

• Phase I Study 100%
• Multiple Myeloma 100%
• Bortezomib 100%
• Maintenance Therapy 100%
• Single Institution 100%
• Natural Killer Cells 20%
• Overall Response Rate 20%
• Pretransplant 20%
• Overall Survival 20%
• CD56+ 20%
• CD8+ 20%
• No Adverse Effect 20%
• Kaplan-Meier Estimator 20%
• Partial Remission 20%
• Stem Cell Engraftment 20%
• Induction Therapy 20%
• Granulocyte Colony-stimulating Factor (G-CSF) 20%
• 2-cycles 20%
• Disease-free Survival 20%
• Cytotoxic T Cells 20%
• Varicella Zoster 20%
• High-dose Melphalan 20%
• Viral Reactivation 20%
• Stem Cell Mobilization 20%

Immunology and Microbiology

• Multiple Myeloma 100%
• Natural Killer Cell 50%
• CD8 50%
• Drug Megadose 50%
• Stem Cell 50%
• Overall Survival 50%
• Varicella Zoster Virus 50%
• Disease Free Survival 50%
• Engraftment 50%
• Granulocyte Colony-Stimulating Factor 50%
• Peripheral Blood Lymphocyte 50%
• Cytotoxic T Cell 50%
• Adverse Effect 50%